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We isolated a human endothelin-1 (ET-I) receptor cDNA from a human placenta cDNA library. The cDNA encodes a 427-amino acid protein 
with seven putative transmembrane domains. The rank order of the binding to the receptor expressed in COS-7 cells was: ET-I > ET-2 >> ET-3. 
The receptor expressed in Xenopus oocytes showed a potent electrophysiological response to 1 x 10 ’ M ET-l under voltage clamp at -60 mV, 
while a much weaker response was produced by 1 x 10 7 M ET-3. Northern blot analysis with RNA from human tissues revealed a single band 
with a size of 4.3 kb in a wide variety of human tissues, especially highly in the blood vessel. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Endothelin-1 (ET-l) was initially identified as a po- 
tent vasoconstrictor peptide with 21 -amino-acid 
residues produced by porcine vascular endothelial cells 
[ 11. Cloning and sequence analyses of the endothelin 
(ET) genes revealed that ETs comprise a peptide family 
consisting of three isopeptides, ET-l, ET-2 and ET-3, 
which have subsequently been found to distribute in a 
wide variety of vascular and non-vascular tissues [2-41. 
Approximately I x 10’ plaques of human placenta cDNA library in 
XZAPll were screened using the “P-labeled Ncol-GcoRI fragment of 
bovine ET-l receptor cDNA as a probe [8,9]. A single clone was 
positively hybridized (phETlR), and restriction fragments of the 
cDNA insert were subcloned into Bluescript (Stratagene, La Jolla, 
CA). Both srrand\ of the cDNA insert were sequenced by the dideoxy 
chain termination merhod [IO]. 
2.2. t\-pres.sion oj humtm ET-I receptor II? COS- 7 cell5 
The discovery of three isopeptides and their different 
biological activities raised the possibility of existence of 
multiple ET receptor subtypes. It has previously been 
shown in vivo that ET-1 and ET-2 are much more po- 
tent vasoconstrictors than ET-3, whereas the three 
isopeptides are roughly equipotent in producing the 
transient vasodilation, suggesting that the receptors 
mediating these opposing responses are different [2,5]. 
These pharmacological findings were further supported 
by detailed radioligand binding studies indicating the 
presence of, at least, two distinct subpopulations of ET 
binding sites; one has higher affinity for ET-l or ET-2 
than ET-3; the other has higher affinity for ET-3 than 
ET-l or ET-2 [6,7]. 
The Xhol-NorI fragment of phET1R was tubcloned into CDMX 
(CDM8-phET1R) [I 11. COS-7 cells were transfected with CDMR or 
CDM8-phET1R (2Oyg of DNA per 100 mm plate) by the calcium 
phosphare method 1121. Twenty-eight hours after tranafection. cells 
were harvested and 5 x 10 cells/well \\ere seeded into a 24.*ell 
culture plate. 
2.3. Comprtifrve binding IC) human ET-I receptor expressed in 
COS- 7 WI0 
Competitive bmding assays of “‘l-ET-1 with unlabeled ET-l, ET-2 
or ET-3, were performed 52 h after transfection as previously 
reported [13]. All determinant, were in duplicate. Background bin- 
ding in the pre,encc of 4 x IO-- M ET-I was 150 cpm. 
2.4. ~lecrroph~siologicul meusuremmls of humun ET-I rrwpptor 
eqx-essrd 111 ?<enopu, 0oc~te.Y 
Recently, we have succeeded in expression cloning of 
the bovine ET-l receptor cDNA using the XenopLrs 
oocyte expression system coupled with the voltage 
clamp method [8]. Here we report the cDNA cloning of 
human ET-l receptor from a human placenta cDNA 
library and gene expression of this receptor in a wide 
variety of human tissues including the blood vessel. 
The mRNA (approximately IO ng) synthesized in vitro from 
phE,tl R by T7 RNA polymerase was injected into Xenopus oocgtes 
[8,14]. Whole-cell currents in response to the application of 1 x 
10 ’ M ET-l, ET-2 or ET-3 under boltage clamp at -60 mV were 
recorded [8,14]. 
2.5. Northern blot h.vbridizntion una1.vse.s oj humun ET-I receptor 
l,lKR;A 
~‘orre.cponr/ence addresa: 1<. Nakao, Second DiLiGon, Department of 
Rledicine, Kyoto University School of Medicine, 54 Shogoin 
Kabbahara-cho. Sakyo-ku, Kyoto 606, Japan. Fau: (81) (75) 7719452 
,4bbreviut~ons: ET, endothelin; ICio, 50% inhibitory concentration 
Total RNA was extracted from human tissues obtained at autopsy 
or operation, and human umbilical vein endotheliat cells purchased 
from Colonetics Corp. (San Diego, CA) [9]. Northern blots of RNA 
on nylon membrane were hybridized with “P~labeled EcoRV-EwRI 
fra>;ment of the insert of phET1R. This study was approbed by the 
ethical commitree on human research of Kyoro University 
(No. 61-98). 
Published by Elsevier Science Publishers B. V. 23 
Volume 287. number I ,2 FEE LETTERS August 1991 
3. RESULTS AND DISCUSSION 
3.1. Nucleotide and deduced utnino acid sequences c?f 
hutnun ET-1 recepior cDNA 
Fig. 1 show the 4105-nucleotide sequence of the 
cloned cDNA containing a 12Wnucleotide open 
reading frame encoding a 427-amino acid protein \vith 
a relative molecular mass of 48726. The nucleotide sc- 
quence of the open reading frame was 91.20;‘0 identical 
to that of the bovine ET-I recepror cDNA and the 
deduced amino acid sequence was 94.60’0 identical to 
that of the bovine ET-l receptor. The nucleotide se- 
quence surrounding the initiation codon agrees well 
M ith the conwib~~s sequence [ 151. The 3 ‘-noncoding 
region contains ATTTA sequences implicated in 
m R N A instability [16]. There is a potential 
polyadenylation signal 22 nucleotides upstream of the 
poly(A)- tail [ 171. Based on the consensus site for signal 
sequence cleavage [18], the N-terminal 20 amino acid 
[residues probably constitute a signal sequence. 
Hydropathicity analysis of the amino acid sequence in- 
dicates that there are 7 hydrophobic clusters of 22-26 
residues, each separated by stretches of hydrophilic 
residues, indicating that the cDNA encodes a protein 
GMT 
TCGCGGCCGCCTCTTGC~TCCCAGAGTGGAtiT~~~TCTGGA(;CTTTGG[;A~AGAC~A~ACAGACT~A~CGTG~CCTCC~AG~C~CGTGCGAGCCCTCGCG 
CGCGCGTACAGTCATCCCGCTGGTCTGACGATT(;TGGAGAGGCGGTGGAGAGAGGCTTCATCCATCCCACCCGGTCGTCGCCGGGGATT~TCCCAGCGACACCTCCCCW;GAGAAGCAG 
TGCCCAGGAAGTmCTGAAGCCGW;GMGCTGI‘GCAGCCGMGCCGCCGCCGCGCC(;GAGCCCGGGACACCGGCCACCCTCCGCGCCACCCACCCTCGCTTTCTCCGGCTTCCTCTGGC 
CCAGGCGCCGCGCGGACCCGGCAGCTGTCTGCGCACGCCGAGCTCCACCGTG AAAAAAAAAGTGAAGGTGTAAAAGCAGCACAAGTGCAATAG 
1 20 40 
MetGl"ThrLe"CysLe"ArgAlaSerPhrTrpLellAlaLeuV~lGlyCysValIleSrrAspAsnProCl"ArgTyrSerTh~A~~~L~"S~~As~~isV~lAspAspPheThrThrPhe 
AT~AAACCCTTTGCCTCAU;GCATCC?‘TTT(;CCTTTT~CTGGCACT~TTGGATGTGT~TCAGTGAT~TCCTGAGAGATACAGCAC~TCT~GC~TCATGT~ATGAT~CACCAC~ 
6O v 80 
ArgGlyThrGl"Le"SerPheLeuValThrThrHisclnP~~Th~As~1.~~~V~lL~"Pr~SerAsnGlySer~etHisAsnTyrCysP~~~GlnGlnTh~LysIleThrSerAlaPheLys 
CGTGGCACAGAGCTCAGCTTCCT~TTACCACTCATCAACCCACTAA~TGGTCCTACCCAGCAATGGCTCAATGCACAACTA~GCCCACAGCA(;ACTAAAATTAC~CAGC~CA 
1 100 120 
TyrllrAsnThrValIleSerCysThrIlrPhr1Ir~ValGlynrtValGlyAsnAlaThrLe"L~uAr~1leIleTyrClnAsnLysCysUrtAr~AsnGlyProAsnAlaLe"IleAla 
TACATTAACACTGTGATATCTTGTACTATTTTCATCATCGTGGG~T(;GT~GG~TGC~CTCTGCTCAGGATCAT~ACCAG~C~TGTATGA~~T~CCCC~CGCGCTGATAGCC 
11 140 160 - 
SerLeuAlaLeuGlyAspLeuIleTyrVaIV~1I1eAspLe~:ProlleA.snValPheLysLeuLe"AlaGlyArgTrpProPheAspHisAsnAspPheGlyValPheLeuCysLysLe" 
AGTC~GCCCTTGGAGA~~TTATCTATCTATGT~TCATTGAT~T~CCTATC~TGTA~~GCTG~T~~T~G~GCT~~C~TTGATCA~~TGAC~~CGTA~TC~GC~GCTG 
III 180 200 
PheProPheLruGlnLysSerSerVnlGlyIleTt~rValLe"Asr~Lr,,CysAlaLr"SerValAspArgTyrArgAlaYalAlaSrrTrpSerAr~ValGlnGlyIleGlyIleProLe" 
TTCCcCTmTGCAGAAGTCCTCGG'IGGGGA'~CACCGTCC‘~(;~CCTCTGCGC'rC~A[;TG~GACAr~TACAGAGCAGTTGCC'~CCT~AGTCG~GTTCA~~~G~Al~CCTTTG 
lV 220 
\ . 240 
ValTt,rAlaIleGl"IleValScrllrTrpIleLeuSerPt~~Il~~L~,,Al~llePr~Gl"AlaIl~GlyPheV~l~etValPr~~P~~eGluTyrAr~GlyGl"Gln~~s yslhrf_ysHet 
GTAACTGCCATTGAAATTGTCT~CAT~TC(~ATC~TGT~CTTTAT~CTGGCCA~T~CTG~G~GA~~CTTCGTCAT~TACCC~TG~TATA~TG~~AG~AT~CCTGTATG 
260 V 280 
Le"AsnAlaThrSerLysPhPHetGl"PheTyrGlnAspValLysAspTrpTrpLe"PheG1yPheTyrPheCysM~~Pr~L~"V~lCysThrAlall~PheTyrThrL~"U~~Th~Cys 
CTCAATGCCACATCAAAATTCATGGAGTTCTACCMGA1'rCTTCTACACCCTCATGACTTGT 
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with 7 membrane-spanning domains, an extracellular N 
tail and a cytoplasmic C tail, which is consistent with 
the superfamily of G protein-coupled receptors. 
As shown in Fig. 1, there are several potential sites 
for post-translational modification: two consensus sites 
for N-glycosylation; six cysteine residues in the N ter- 
minus of the cytoplasmic C tail, one of which may be 
palmitoylated as in the/J-adrenergic receptor [19]; and 
serine residues potentially able to be phosphorylated by 
serine/threonine kinases [20]. 
3.2. Ligand selectivity of human ET-I receptor 
expressed in CDS-7 cells 
To confirm that the cDNA clone we have obtained in- 
deed encodes a receptor for ET-l, we constructed the 
expression vector CDM8-phET1 R. The ligand binding 
property of the receptor expressed by the 
CDM8-phET1R was determined by competitive binding 
of “‘I-ET-1 in the presence of unlabeled ET-l, ET-2 or 
ET-3 (Fig. 2). The amount of ‘251-ET-l binding in 
COS-7 cells transfected with control plasmid CDMX 
was indistinguishable from the level of non-specific 
‘251-ET-l binding in the presence of excess unlabeled 
ET-1 (data not shown). Competition for 1251-ET-i bin- 
ding with unlabeled ET-l gave an I& of 3.0 x lo-’ M. 
ICsO of ET-2 was 6.1 x lo-’ M and approximately two 
times larger than IC& of ET-I. IC~O of ET-3 was more 
than 1 x 10m6 M. Thus, the rank order of the binding 
affinity to the human ET-l receptor was ET-l 3 ET-2 
+ ET-3. 
The relative potency of the binding of ET-2 to human 
ET- 1 receptor was slightly different from that to bovine 
ET- 1 receptor [8]. This difference might be explained in 
part by the difference of the binding assay method. In 
our previous study, we used membrane preparation for 
01’ 
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-log [ Peptide] CM) 
big, 2. Competitive binding 01 “‘I-ET-1 to COS-7 cells tranFfected 
with C‘DI\4%phETlR. “‘I-ET-1 (50 pM) \\a5 incubated in the absence 
or presence of various concentrations (lO~“‘-lO~h X4) of ET-I (o), 
ET-2 (m) or ET-3 (A). Data are expressed a$ the percentage of specific 
“‘I-ET-I binding and values are the mean\ of duplicate 
determinations. 
A 
ET-3 
1 
ET-l 
1 
B 
Vehicle 
1 
1 
0 
0 
m L- 
5 mill 
++ i 
Fig. 3. Current ttacc recorded fr-om Xwo~~u.\ oocytes injected with 
the in vitro \ynthesi/ed human ET-I receptor mRl\rA. I x IO-- M 
ET-I, I x IO-- &I ET-3 (A) and vehicle (B) \\t’re applied. I>own\lard 
deflection indicates inward current. 
the binding assay, but in the present study, we used in- 
tact transfected COS-7 cells. 
3.3. Electrophysiological responses via human ET-l 
receptor expressed in Xenopus oocytes 
Electrophysiological responses via the human ET-l 
receptor to ET-l, ET-2 or ET-3 were examined in the 
Xenopus oocyte expression system coupled with the 
voltage clamp method as shown in Fig. 3. Twenty 
seconds after the application of 1 x lo-’ M ET-I, a po- 
tent inward current was recorded under voltage clamp 
at -60 mV in oocytes injected with the in vitro syn- 
thesized mRNA of the receptor (Fig. 3A). A similar in- 
ward current was also recorded by 1 x lo-’ M ET-2 
(data not shown). In contrast, a much weaker current 
was induced by the application of 1 x lo-’ M ET-3 
(Fi,g. 3A). The endothelin-evoking currents were fluc- 
tuating and long-lasting, and were thus characteristic of 
Ca2+-activated chloride currents [21]. No currents were 
recorded by vehicle (vehicle was ND 96 containing 
0.1% Triton X-100 and 0.1% gelatin) (Fig. 3B). 
3.4,. ET-l receptor mRNA in human tissues 
-To elucidate the expression of human ET-I receptor 
mRNA in various human tissues, we used a 826-bp 
EcoRV-EcoRI fragment of human ET-l receptor 
cDNA (nucleotides 256-1081) as a probe in the Nor- 
thern blotting. As shown in Fig. 4, this probe detected 
a single band of mRNA with a size of 4.3 kb at the 
highest abundance in the aorta, at high levels in the 
lung, atrium, colon and placenta, at moderate levels in 
the cerebral cortex, cerebellum, ventricle, kidney, 
adrenal and duodenum. We did not detect any hybridiz- 
ing signal in the liver. No hybridizing band was detected 
in human endothelial cells of the umbilical vein. 
The highest level of ET-l mRNA in the aorta and no 
25 
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18S- 
hybridizing signal in the endothelial cells suggest that 
the ET-I receptor mRNA is expressed in vascular 
smooth muscle cells. This notion is consistent with the 
previous finding that ET-l and ET-2 inhibited ‘“‘I-ET-I 
binding to rat A-IO vascular smooth muscle cells but 
ET-3 failed to compete for ‘251-ET-1 binding to the 
same cells [7]. Since no hybridizing band of the non- 
isopeptide-selective subtype of EX receptor mRNA was 
reported to be detected in the rat aorta and A-10 
vascular smooth muscle cells [22], ET-I receptor en- 
coded by the cDNA cloned in the present study is a ma- 
jor subtype of the ET receptor expressed in vascular 
smooth muscle ceils. It is conceivable that ET-l released 
from the endothelial cells binds to the ET-I receptor in 
vascular smooth muscle cells and works as a local 
regulator in cardiovascular homeostasis. 
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